PDAC - Celsion gives enrollment update on early-stage ThermoDox pancreatic cancer study

Celsion (CLSN) starts enrollment in Oxford University’s Phase I PanDox study with the company's ThermoDox in conjunction with Focused Ultrasound in patients with pancreatic cancer. ThermoDox, a heat activated liposomal doxorubicin, will be administered intravenously in 12 patients with non-resectable pancreatic ductal adenocarcinoma ((PDAC)) and locally activated by focused ultrasound-mediated hyperthermia.The primary endpoint of the two-arm 18-subject PanDox study is enhanced uptake of doxorubicin in pancreatic tumors using ThermoDox and Focused Ultrasound ((FUS)), compared to systemic delivery of free doxorubicin.The company said that the study is expected to be completed by December 2022.Shares up more than 2% premarket.

For further details see:

Celsion gives enrollment update on early-stage ThermoDox pancreatic cancer study